US stock · Healthcare sector · Medical Instruments & Supplies
B
Becton, Dickinson and Company
BDX
NYSE241.12
USD
-0.65
(-0.27%)
Market Closed
43.15P/E
18Forward P/E
1.79P/E to S&P500
68.482BMarket CAP
1.47%Div Yield
Upcoming Earnings
2 Aug-7 Aug
Shares Short
5/15/23
2.56M
Short % of Float
0.90%
Short % of Shares Outs.
0.90%
% Held by Insiders
0.35%
% Held by Institutions
89.75%
Beta
0.56
PEG Ratio
2.01
52w. high/low
269.06/215.90
Avg. Daily Volume
1.05M
Return %
Stock
S&P 500
1 year
(4.66)
5.88
3 years
1.51
40.76
5 years
8.41
52.43
Scale: |
High
Low
93.24
58.14
79.97
60.40
85.50
66.47
89.75
69.59
80.56
71.56
110.94
78.73
142.56
105.21
157.50
128.87
181.75
129.50
229.69
161.50
265.87
208.62
275.48
210.72
286.72
197.75
267.37
235.13
280.62
215.90
266.70
228.62
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
25.94
29.29
29.78
31.46
35.40
37.52
41.27
43.69
50.77
58.69
55.23
61.86
64.05
61.36
69.99
65.23
66.10
Earnings per share
3.63
4.61
5.12
5.62
5.75
5.69
6.63
6.13
3.43
4.59
5.02
1.20
4.57
3.13
7.23
5.65
5.36
FCF per share
2.70
4.24
4.23
4.74
5.02
5.87
4.71
5.64
5.41
8.66
8.33
7.63
8.78
9.78
11.81
5.18
4.05
Dividends per share
0.98
1.14
1.32
1.48
1.63
1.79
1.98
2.18
2.39
2.64
3.09
3.59
3.65
3.68
3.62
3.74
3.88
CAPEX per share
2.36
2.67
2.91
2.70
2.74
2.69
3.01
3.38
3.13
3.38
3.32
3.46
3.55
2.90
4.26
3.36
3.33
Book Value per sh.
17.79
20.20
21.39
23.19
21.83
20.13
25.84
26.14
35.38
35.89
59.14
81.26
78.10
85.19
81.85
87.46
89.60
Comm.Shares outs.
245
244
240
234
221
205
195
193
203
213
219
258
270
279
289
289
285
Avg. annual P/E ratio
21.5
17.6
13.5
13.3
14.0
13.4
14.7
19.4
41.8
35.5
38.6
196.0
53.9
78.7
34.3
44.3
43.1
P/E to S&P500
1.2
0.8
0.2
0.6
0.9
0.9
0.9
1.1
2.1
1.6
1.6
7.8
2.2
2.1
1.1
2.1
1.8
Avg. annual div. yield
1.3%
1.4%
1.9%
2.0%
2.0%
2.3%
2.0%
1.8%
1.7%
1.6%
1.6%
1.5%
1.5%
1.5%
1.5%
1.5%
1.6%
Revenue (m)
6,360
7,156
7,161
7,372
7,829
7,708
8,054
8,446
10,282
12,483
12,093
15,983
17,290
17,117
20,248
18,870
18,809
Operating margin
18.9%
21.7%
23.0%
22.7%
22.5%
20.2%
15.6%
19.0%
10.4%
11.5%
12.2%
9.4%
10.2%
8.7%
13.8%
12.1%
8.9%
Depreciation (m)
441
477
470
502
504
511
546
562
891
1,114
1,088
1,978
2,253
2,154
2,273
2,229
2,406
Net profit (m)
890
1,127
1,232
1,318
1,271
1,170
1,293
1,185
695
976
1,100
311
1,233
874
2,092
1,635
1,616
Income tax rate
28.9%
27.4%
26.0%
29.2%
26.3%
24.6%
20.3%
22.1%
6.0%
9.0%
(12.7)%
73.5%
(4.8)%
11.3%
6.7%
8.3%
6.2%
Net profit margin
14.0%
15.7%
17.2%
17.9%
16.2%
15.2%
16.1%
14.0%
6.8%
7.8%
9.1%
1.9%
7.1%
5.1%
10.3%
8.7%
8.6%
Working capital (m)
1,652
2,198
2,870
2,834
2,845
3,344
3,743
3,896
1,659
1,967
15,291
195
1,009
3,133
2,212
8,133
2,283
Long-term debt (m)
956
953
1,488
1,495
2,485
3,761
3,763
3,768
11,370
10,550
18,667
18,894
18,081
17,224
17,110
14,763
16,010
Equity (m)
4,362
4,936
5,143
5,435
4,828
4,136
5,042
5,053
7,165
7,634
12,948
20,994
21,082
23,765
23,677
25,301
25,689
ROIC
15.0%
17.4%
16.7%
16.5%
15.5%
13.4%
13.3%
12.6%
4.7%
6.3%
4.9%
1.1%
4.1%
2.8%
5.4%
3.8%
3.3%
Return on capital
16.9%
19.6%
18.3%
19.2%
17.3%
14.7%
13.7%
13.3%
4.1%
5.7%
4.0%
3.5%
3.5%
2.8%
5.0%
4.1%
3.1%
Return on equity
20.4%
22.8%
23.9%
24.2%
26.3%
28.3%
25.6%
23.5%
9.7%
12.8%
8.5%
1.5%
5.8%
3.7%
8.8%
6.5%
6.3%
Plowback ratio
73.1%
75.3%
73.9%
70.6%
71.4%
66.9%
58.4%
64.5%
30.2%
42.4%
38.5%
(198.1)%
20.2%
(17.4)%
49.9%
39.2%
31.7%
Div.&Repurch./FCF
84.5%
62.1%
82.1%
94.0%
160.0%
30.5%
42.0%
38.6%
44.3%
30.5%
37.1%
47.1%
21.0%
(69.3)%
81.9%
105.6%
95.9%
Capital Structure
4 May · 2023 | Q2
All numbers in millions
Total liabilities
$ 28,705
Total assets
$ 54,394
Long-term debt
$ 16,010
Cash and equiv.
$ 1,981
Goodwill
$ 24,780
Retained earnings
$ 15,563
Common stock
284
Enterprise Value
$ 82,511
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
2,845
2,295
1,014
Receivables
2,398
2,497
2,191
Inventory
2,743
2,866
3,224
Other
983
638
(107)
Current assets
8,969
8,838
8,141
Acc. Payable
1,355
1,793
2
Debt due
706
500
2
Other
3,775
4,333
4
Current liabilities
5,836
6,626
8
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(6.81)%
4.67%
10.64%
Cash flow
(56.15)%
1.12%
10.97%
Earnings
(21.85)%
96.22%
35.17%
Dividends
3.24%
3.95%
12.59%
Book value
6.86%
4.91%
22.22%
Insider Trading
Type
Shares
Date
Jones Christopher Ian Montague
Award
118
05/05/23
Byington Carrie L
Award
118
05/05/23
Quinn Michelle
InKind
99
05/01/23
Neal Shana Carol
InKind
731
04/04/23
Neal Shana Carol
Award
8,229
04/04/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
5,315
4,907
4,890
5,135
20,247
2022
4,995
5,011
4,641
4,761
19,408
2023
4,586
4,821
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
3.47
1.03
1.81
0.92
7.23
2022
2.34
1.57
1.24
0.99
6.15
2023
1.79
1.62
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.91
0.91
0.90
0.90
3.62
2022
0.94
0.93
0.94
0.93
3.74
2023
0.99
0.99
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
CEO:
Mr. Thomas E. Polen Jr.
Full-time employees:
77,000
City:
Franklin Lakes
Address:
1 Becton Drive
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.